

# An investigation into whether tight glucose control improves mortality in patients admitted to combined Intensive Therapy Unit/High Dependency Unit (ITU/HDU)

<b>Submission date</b> 30/09/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 30/09/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 05/12/2014	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Malcolm Watters

### Contact details

The Great Western Hospital  
Marlborough Road  
Swindon  
United Kingdom  
SN3 6BB

-  
abc@email.com

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

N0247130746

# Study information

## Scientific Title

An investigation into whether tight glucose control improves mortality in patients admitted to combined Intensive Therapy Unit/High Dependency Unit (ITU/HDU)

## Study objectives

Does intensive glucose control improve outcome in a population of Intensive Therapy Unit/High Dependency Unit (ITU/HDU) patients?

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Not Applicable

## Interventions

Group 1: Intensive insulin therapy - the blood glucose will be maintained between 4.4 and 6.1 mmol/L using intravenous insulin therapy

Group 2: Conventional insulin therapy - the blood glucose will be maintained between 10.0 and 11.1 mmol/L using intravenous insulin therapy

## Intervention Type

Drug

## Phase

Not Applicable

**Drug/device/biological/vaccine name(s)**

Insulin

**Primary outcome measure**

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

10/03/2003

**Completion date**

30/06/2005

## Eligibility

**Key inclusion criteria**

ITU/HDU patients

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

10/03/2003

**Date of final enrolment**

30/06/2005

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**  
**The Great Western Hospital**  
Swindon  
United Kingdom  
SN3 6BB

## **Sponsor information**

**Organisation**  
Department of Health

**Sponsor details**  
Richmond House  
79 Whitehall  
London  
United Kingdom  
SW1A 2NL

**Sponsor type**  
Government

**Website**  
<http://www.dh.gov.uk/Home/fs/en>

## **Funder(s)**

**Funder type**  
Government

**Funder Name**  
Swindon and Marlborough NHS Trust (UK)

## **Results and Publications**

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration